PAP
ENGN icon

Persistent Asset Partners’s enGene Therapeutics ENGN Stock Holding History

Persistent Asset Partners’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
+114,493
New +$467K 0.06% 217

Other funds holding ENGN

FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Nextech Invest
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Persistent Asset Partners's ENGN Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 114,493 shares worth $198K. The stake represents 0.06% of the portfolio and ranks #217 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Persistent Asset Partners held 114,493 shares of enGene Therapeutics worth $198K as of Q2 2026.
  • enGene Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • enGene Therapeutics made up 0.06% of Persistent Asset Partners's portfolio in Q2 2026, its #217 holding.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.